Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Jesus San-Miguel,1 Saad Z. Usmani,2 Maria-Victoria Mateos,3 Niels W.C.J. van de Donk,4 Jonathan L. Kaufman,4 Philippe Moreau,4 Albert Oriol,7 Torben Plesner,9 Lotfi Benboubker,6 Kevin Liu,10 Peter Hellmann,11 Tara Masterson,12 Pamela L. Clemens,13 Man Luo,12 Andrew Farnsworth,13 Hareth Nahi14 and Ajai Chari15

1Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain; 2Levine Cancer Institute/Atrium Health, Charlotte, NC, USA; 3University Hospital of Salamanca/IBSAL, Salamanca, Spain; 4Amsterdam University Medical Center, Department of Hematology, Amsterdam, the Netherlands; 5Winship Cancer Institute, Emory University, Atlanta, GA, USA; 6University Hospital of Nantes, Nantes, France; 7Institut Català d’Oncologia, HGTIP, Barcelona, Spain; 8Vejele Hospital and University of Southern Denmark, Vejele, Denmark; 9Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France; 10Janssen Research & Development, LLC, Raritan, NJ, USA; 11Janssen Research & Development, Beerse, Belgium; 12Janssen Research & Development, LLC, Spring House, PA, USA; 13Janssen Research & Development, LLC, High Wycombe, UK; 14Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden and 15Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA

ABSTRACT

Intravenous daratumumab is approved for the treatment of multiple myeloma. In part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and an efficacy similar to that of intravenous daratumumab. Part 2 of PAVO evaluated a concentrated, pre-mixed co-formulation of daratumumab and rHuPH20 (DARA SC). Patients who had received two or more prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, were given daratumumab (1,800 mg) and rHuPH20 (30,000 U) in 15 mL subcutaneously over 3 to 5 minutes as per the approved intravenous monotherapy dosing schedule. Primary endpoints were daratumumab trough concentration at the end of weekly dosing (just prior to the day 1 dose of cycle 3) and safety. Twenty-five patients were enrolled in PAVO part 2. DARA SC achieved daratumumab trough concentrations similar to or greater than those achieved with intravenous daratumumab 16 mg/kg. The adverse event profile of DARA SC was consistent with that of intravenous daratumumab, with no new safety concerns and a lower infusion-related reaction rate. At a median follow-up of 14.2 months, the overall response rate was 52%, the median duration of response was 15.7 months, and the median progression-free survival was 12.0 months. DARA SC 1,800 mg was well tolerated in relapsed/refractory multiple myeloma, with a low infusion-related reaction rate and reduced administration time. Daratumumab serum concentrations following DARA SC were consistent with those following intravenous dosing, and deep and durable responses were observed. Based on these results, ongoing studies are investigating DARA SC in the treatment of multiple myeloma and other conditions. (ClinicalTrials.gov identifier: NCT02519452).

Introduction

Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor1-4 and immunomodulatory5-7 mechanism of action. The direct on-tumor actions of daratumumab are mediated by complement-dependent cytotoxici-
city, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and apoptosis. The immunomodulatory actions of daratumumab lead to modulation of the tumor microenvironment, including the depletion of CD38+ immunosuppressive cells, which may explain the clonal expansion of cytotoxic T cells, increase in helper T cells, and increase in granzyme B+ CD8+ T cells observed following exposure to this drug.6,7

Intravenous (IV) daratumumab 16 mg/kg is approved as a monotherapy and in combination with bortezomib/dexamethasone, lenalidomide/dexamethasone, or pomalidomide/dexamethasone (in the USA) in patients with relapsed or refractory (RR) multiple myeloma (MM).8 Daratumumab 16 mg/kg IV is also approved in combination with bortezomib/melphalan/prednisone or lenalidomide/dexamethasone (in the USA) for patients with newly diagnosed MM who are ineligible for autologous stem cell transplantation, and in combination with bortezomib/thalidomide/dexamethasone (in the USA) for patients with newly diagnosed MM who are eligible for autologous stem cell transplantation.9 In clinical studies of daratumumab, the median durations of the first, second, and subsequent daratumumab IV infusions were 7.0, 4.3, and 3.4 hours (h), respectively.1 For the convenience of patients and healthcare providers, the first daratumumab 16 mg/kg IV dose may be split over 2 days (8 mg/kg administered on days 1 and 2 of cycle 1), which is associated with a shorter median infusion duration of 4.2 h on day 1 of cycle 1.6,8,11 In addition to split-dose administration of daratumumab, alternative approaches to reducing the duration of the first daratumumab infusion include administering a low priming dose on day 1 of cycle 1 and the remainder of the 16 mg/kg IV dose on day 2, or giving an 8 mg/kg IV dose on day 1 of cycle 1 before proceeding with the 16 mg/kg IV dose from day 8 of cycle 1 onwards.12 Furthermore, a shorter, 90-minute (min) infusion for subsequent (day 15 of cycle 1 and beyond) 16 mg/kg IV administrations of daratumumab was shown to be well tolerated.13 Infusion-related reactions (IRR) occur in approximately 50% of patients treated with IV daratumumab; these reactions are manageable and occur primarily during the first infusion.4

Given the infusion time required for IV administration and the incidence of IRR associated with daratumumab, a subcutaneous (SC) delivery method is in development, with the goal of shortening the duration of infusion without compromising the safety or efficacy of the drug. SC administration of daratumumab may be associated with a lower risk of IRR, improved tolerability due to a more gradual systemic absorption of the drug, and greater convenience for both patients and healthcare providers by reducing infusion times.

Recombinant human hyaluronidase PH20 (rHuPH20; ENHANZÆ drug delivery technology, Halozyme, Inc., San Diego, CA, USA) depolymerizes hyaluronan in the SC space, allowing rapid administration of large volumes of injected drugs, thus facilitating SC delivery.14 A mix-and-deliver formulation of daratumumab (20 mg/mL) and rHuPH20 (DARA-MD), given SC by means of a syringe pump at two dose levels (DARA-MD 1,200 mg and DARA-MD 1,800 mg) over 20 to 30 min, was evaluated in part 1 of PAVO, a phase Ib study in patients with RRMM.15 Results from part 1 showed that SC administration of daratumumab is feasible in patients with MM. DARA-MD was well tolerated, with low rates of IRR (23%). The serum concentrations achieved with the 1,800 mg dose of DARA-MD were consistent with those observed for daratumumab 16 mg/kg IV in patients with RRMM. Moreover, the efficacy of the 1,800 mg dose of DARA-MD was comparable to that of daratumumab 16 mg/kg IV in a similar population of patients.16 At the 1,800 mg dose level of DARA-MD, the overall response rate (ORR) was 42%, and responses were deep and durable, with four (9%) patients achieving a stringent complete response.17

Based on the results from part 1 of the PAVO study, a concentrated, pre-mixed co-formulation of daratumumab 1,800 mg (120 mg/mL) and rHuPH20 (DARA SC) with a smaller injection volume (15 mL for DARA SC vs. 60 mL for DARA-MD 1,200 mg and 90 mL for DARA-MD 1,800 mg) and shorter injection time was developed, enabling manual SC injection into the abdomen.18 This report describes part 2 of PAVO, which investigated the safety, pharmacokinetics (PK), and efficacy of DARA SC in patients with RRMM.

Methods

Study design and patients

PAVO (MMY1004) is a phase Ib, open-label, multicenter, dose-finding, proof-of-concept study. Detailed eligibility criteria have already been published.19 Briefly, patients were ≥18 years of age, had RRMM and had received two or more prior lines of treatment, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), and were naïve to anti-CD38 therapy. In part 1, DARA-MD was administered by SC infusion over 20 to 30 min through a syringe pump to determine the recommended dose for part 2. In part 2, a concentrated co-formulation of the selected daratumumab dose (1,800 mg) and rHuPH20 concentration (30,000 U; in 15 mL) in a single, pre-mixed vial was administered over 3 to 5 min by manual SC injection (DARA SC) at alternating locations in the periumbilical area of the abdominal wall. Treatment was given in 28-day cycles: once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter until disease progression or unacceptable toxicity. All patients remained in the hospital for observation for at least 24 h after the end of the SC injection on day 1 of cycle 1.

Inpatient observation after subsequent doses was implemented if deemed necessary based on safety observations.

Endpoints and assessments

The primary endpoints were daratumumab trough concentration (Ctrough) at the end of weekly dosing (just prior to administration of the day 1 dose of cycle 3) and safety. Secondary endpoints included ORR and complete response rate.

Blood samples for PK analysis were collected on days 1, 2, 3, 4, 8, 15, and 22 of cycle 1; days 1, 8, 15, 22, 23, and 25 of cycle 2; day 1 of cycles 3, 4, 6, and 8; and 4 and 8 weeks after the final dose of study medication. Blood samples collected prior to dosing on days 1 and 15 of cycle 1, day 22 of cycle 2, and day 1 of cycle 4 as well as 4 and 8 weeks after the end of treatment were assessed for anti-daratumumab antibodies and anti-rHuPH20 antibodies.

Safety assessments included adverse-event monitoring, physical examinations, electrocardiograms, injection-site evaluations, clinical laboratory parameters, vital sign measurements, and Eastern Cooperative Oncology Group Performance Status. Adverse events were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.20

Responses were assessed according to International Myeloma Working Group consensus recommendations21 at the beginning...
of each cycle. Disease evaluations were performed by a central laboratory until disease progression or end of treatment.

Statistical analyses
The primary endpoint of $C_{\text{trough}}$ at the end of weekly dosing (prior to the day 1 dose of cycle 3) was evaluated in patients who received all eight weekly doses of DARAZA SC and provided a pre-dose PK sample on day 1 of cycle 3 (PK-evaluable population). All other PK analyses were performed on the PK-analysis population, which included patients who received at least one dose of study drug and provided one or more post-infusion PK samples. The safety population included all patients who received at least one dose of study drug.

The study protocol was approved by the clinical study sites’ institutional review boards or ethics committees. Additional details on the study design, statistical analyses, and study supervision are provided in the Online Supplementary Appendix.

Results

Patients and treatment
At the clinical cutoff date of December 14, 2018, 25 patients had been enrolled in part 2 of the study and had received DARAZA SC 1,800 mg. The patients’ median age was 68 (range, 51-85) years, and 24% of patients were ≥75 years of age (Table 1). The median number of prior lines of therapy was three (range, 2-9); 96% and 92% of patients had received prior treatment with bortezomib and lenalidomide, respectively. Fifty-six percent of patients were refractory to both a PI and an IMiD, and 76% of patients were refractory to the last line of therapy. Of the 16 patients with available cytogenetic data, four (25%) had a high-risk cytogenetic abnormality at baseline: two had del17p, one had t(4;14), and one had t(14;16).

Of the 25 patients treated with DARAZA SC during part 2 of the study, 19 (76%) discontinued treatment: 17 (68%) due to progressive disease and two (8%) due to physicians’ decision (both had unconfirmed progressive disease). At the clinical cutoff date, the median duration of follow-up was 14.2 (range, 2.4-18.2) months.

Pharmacokinetics and immunogenicity
PK results for $C_{\text{trough}}$ on day 1 of cycle 3 are presented for the PK-evaluable population (n=22); all other PK data are presented based on the PK-analysis population (n=25). The linear mean daratumumab serum concentration profiles after cycle 1 (first dose) and after the last weekly dose (eighth dose) are shown in Figure 1. Daratumumab serum concentrations after SC administration were sustained from 48 h post-dose onwards until the end of the dosing interval (Figure 1A). SC administration of daratumumab was followed by slow systemic absorption as opposed to the immediate systemic availability following IV administration (Figure 1A). However, the maximum $C_{\text{trough}}$ was similar or higher following DARAZA SC 1,800 mg than after the 16 mg/kg IV dosing of daratumumab (Figure 1B and Table 2).

Simulation of mean concentration-time profiles of daratumumab following SC and IV dosing revealed that the $C_{\text{trough}}$ following DARAZA SC 1,800 mg dosing remained higher than after 16 mg/kg IV dosing throughout the dosing regimen (Figure 2). For SC dosing, the mean maximum concentration ($C_{\text{max}}$) was lower during early weekly dosing but was higher at the end of weekly dosing and during every-2-week dosing (Figure 2). After reaching every-4-week dosing, the $C_{\text{trough}}$ for DARAZA SC 1,800 mg was similar to that for the 16 mg/kg IV dosing of daratumumab overall (Figure 2). The mean and median $C_{\text{trough}}$ values for end of weekly dosing (day 1 of cycle 3) in PAVO part 2, as well as in patients receiving daratumumab 16 mg/kg IV as monotherapy in the GEN501 part 2 and SIRIUS studies, are summarized in Table 2.

Of the 25 patients, one (4%) patient was positive for anti-daratumumab antibodies; the antibodies were neutralizing and transient (detected only at week 4 after treatment). This patient experienced no IRR and had a best response of stable disease. One (4%) patient was positive for anti-rHuPH20 antibodies at baseline, and four (16%) patients were positive for anti-rHuPH20 antibodies during treatment; all the antibodies were non-neutralizing. Among the four patients who were positive for anti-

---

Table 1. Baseline demographics and clinical characteristics of the all-treated population.

| Characteristic          | DARA SC 1,800 mg (n=25) |
|-------------------------|-------------------------|
| Age, years              |                         |
| Median (range)          | 68 (51-85)              |
| ≥75, n (%)              | 6 (24.0)                |
| Median (range) weight, kg| 70.9 (52.0-104.5)       |
| Baseline EOCG Performance Status, n (%) |          |
| 0                       | 11 (44.0)               |
| 1                       | 13 (52.0)               |
| 2                       | 1 (4.0)                 |
| ISS stage, n           | 24                      |
| I, n (%)                | 13 (54.2)               |
| II, n (%)               | 5 (20.8)                |
| III, n (%)              | 6 (25.0)                |
| Median (range) time from diagnosis, years | 5.9 (2.1-12.8)         |
| Type of myeloma, n      | 24                      |
| IgG, n (%)              | 13 (54.2)               |
| Cytogenetic risk, n     | 16                      |
| Standard risk, n (%)    | 12 (75.0)               |
| High risk, n (%)        | 4 (25.0)*               |
| t(4;14)                 | 1 (6.3)                 |
| t(14;16)                | 1 (6.3)                 |
| del17p                  | 2 (12.5)                |
| Prior lines of therapy, n (%) |                   |
| Median (range)          | 3 (2-9)                 |
| ≤3                      | 17 (68.0)               |
| >3                      | 8 (32.0)                |
| Prior ASCT, n (%)       | 17 (68.0)               |
| Prior PI, n (%)         | 25 (100)                |
| Bortezomib              | 24 (96.0)               |
| Prior IMiD, n (%)       | 25 (100)                |
| Lenalidomide            | 23 (92.0)               |
| Refractory to, n (%)    |                         |
| Bortezomib              | 16 (64.0)               |
| Lenalidomide            | 14 (56.0)               |
| Both PI and IMiD        | 14 (56.0)               |
| Last line of therapy    | 19 (76.0)               |

DARA: daratumumab; SC: subcutaneous; EOCG: Eastern Cooperative Oncology Group; ISS: International Staging System; ASCT: autologous stem cell transplantation; PI: proteasome inhibitor; IMiD: immunomodulatory drug; *ISS stage is derived based on the combination of serum β2-microglobulin and albumin. *Assessed by fluorescence in situ hybridization or karyotyping. **Consists of two patients with del17p, one patient with t(4;14), and one patient with t(14;16).
rHuPH20 antibodies during treatment, one patient experienced a mild IRR on day 1 of cycle 1, and best responses were partial response (1 patient), stable disease (2 patients), and progressive disease (1 patient).

Safety
The adverse event profile of DARA SC was consistent with the known safety and tolerability profile of IV daratumumab. The most frequently reported treatment-emergent adverse events (TEAE) were lymphopenia (32%), arthralgia (28%), back pain (28%), and thrombocytopenia, diarrhea, and nasopharyngitis (24% each) (Table 3). The most common grade 3/4 TEAE was lymphopenia (20%) (Table 3). No treatment discontinuations due to TEAE were observed. Serious TEAE were reported in six (24%) patients who received DARA SC but were not considered related to the study drug. One patient died during part 2 of the study due to disease progression in the context of MM-related amyloid light chain (AL) amyloidosis (clinically significant cardiac involvement was not present); this death was not considered related to DARA SC. A secondary primary malignancy was observed in one patient (metastatic adenocarcinoma of prostate). There were no reports of tumor lysis syndrome or intravascular hemolysis.

The incidence and severity of IRR was low with DARA SC 1,800 mg. Among the 25 patients who received DARA SC 1,800 mg, four (16%) reported IRR, the majority of which occurred on day 1 of cycle 1. The median time to onset of an IRR was 70 (range, 9-80) min. Patient 1 experienced grade 3 hypertension, grade 2 chills, and grade 2 dyspnea. Patient 2 experienced grade 1 allergic rhinitis, patient 3 experienced grade 1 sneezing, and patient 4 experienced grade 3 hypertension. Patients 1, 2, and 3 experienced their IRR following the first injection (day 1 of cycle 1), whereas patient 4 experienced the IRR following the ninth injection (day 1 of cycle 3). The IRR of grade 3 hypertension were reversible, and both occurred in patients with a medical history of hypertension. There were no grade 4 IRR and no discontinuations due to IRR.

Injection-site TEAE were observed in three (12%) patients; these included injection-site induration, injection-site discoloration, erythema, and hematoma (n=1 each; all grade 1 severity). Erythema and induration were objectively measured for all injections, regardless of attribution as a TEAE. Measurable erythema (24%) and measurable induration (4%) at the injection site resolved within 1 h.

Efficacy
At a median follow-up of 14.2 months, the ORR with DARA SC 1,800 mg was 52%, which included a complete response in one (4%) patient, very good partial responses in seven (28%) patients, and partial responses in five (20%) patients (Figure 3A). The median time to best response was 1.02 (range, 1.0-12.1) months, and the median duration of response was 15.7 (range, 4.6-not estimable) months. Among 13 responders, three responses deepened over time (Figure 3B); one patient with an initial partial response at month 2 went on to achieve a complete response at month 12, and two patients who achieved initial partial responses at month 1 went on to achieve very good partial responses.
Figure 2. Simulation of mean concentration-time profiles of daratumumab following subcutaneous and intravenous dosing.21 QW: weekly; Q2W: every 2 weeks; Q4W: every 4 weeks; SC: subcutaneous; IV: intravenous; DARA: daratumumab. The dosing schedule is once weekly in cycles 1 and 2, every 2 weeks in cycles 3 through 6, and every 4 weeks thereafter. Simulations were conducted based on a population pharmacokinetic (PK) model developed for daratumumab following SC and IV administration using scheduled dosing and estimated individual PK parameters. Serum concentration-time data (from the PAVO, GEN501, and SIRIUS studies) were used for the population PK model development using a nonlinear mixed-effects modeling (NONMEM®, version 7.2) approach with the first-order conditional estimation with interaction method. The daratumumab SC model was based on a previous population PK model for daratumumab IV21 except for the absorption, which was described by a first-order process and a relative bioavailability parameter.

Discussion

PAVO is the first clinical study to evaluate the safety, PK, and efficacy of SC administration of daratumumab in combination with rHuPH20. The results from this study demonstrate that daratumumab co-formulated with rHuPH20 is well tolerated, has an acceptable PK profile, and achieves deep and durable responses in patients with RRMM. In part 1 of the study, dose escalation of a first-generation mix-and-deliver formulation of daratumumab and rHuPH20 (DARA-MD) showed that daratumumab SC administration is feasible in patients with RRMM.22 DARA-MD 1,800 mg had a PK profile and produced clinical responses that were consistent with those of IV infusion of daratumumab 16 mg/kg and was well tolerated, with a low rate of IRR. Based on the promising safety and efficacy observed with DARA-MD during part 1 of PAVO, a pre-mixed co-formulation of daratumumab 1,800 mg with rHuPH20 (DARA SC), which has a smaller injection volume and is administered over 3 to 5 min, was investigated in part 2 of the study.

Population PK and exposure-response analyses of daratumumab IV monotherapy in patients with MM revealed that the daratumumab maximum Ctrough is strongly related to ORR.23 In these studies, the maximum Ctrough occurred prior to daratumumab dosing on day 1 of cycle 3 with daratumumab monotherapy administered with the same dosing schedule used in the PAVO study.23 Based on these findings, Ctrough at the end of weekly dosing (just prior to the dose on day 1 of cycle 3) was selected as the primary PK endpoint for the PAVO study. DARA SC 1,800 mg achieved similar or greater maximum Ctrough values compared with those of standard IV dosing (16 mg/kg) at day 1 of cycle 3 (i.e., at the end of weekly dosing). The mean Ctrough at day 1 of cycle 3 (pre-dose) was 952 µg/mL after eight weekly doses of DARA SC 1,800 mg compared with 617 µg/mL (GEN501 part 2) and 573 µg/mL (SIRIUS) after weekly dosing with IV daratumumab.22,23,24 Daratumumab serum concentrations were sustained from 48 h post-dose onwards until the end of the dosing interval. Although DARA SC is administered at a fixed dose, while IV daratumumab is administered by weight-based dosing, interpatient PK variability of the two dosing methods was comparable.23,24 Due to the small sample size in part 2 of PAVO, the relationship between the PK of DARA SC and patients’ body weight could not be assessed. However, in a body-weight–based subgroup analysis of the phase III COLUMBA study (NCT032777105), DARA SC achieved adequate exposure that was consistent with that of IV daratumumab, regardless of body weight.25 In patients weighing ≤65 kg, the higher mean maximum Ctrough observed with DARA SC versus IV daratumumab did not have a clinically relevant effect on safety, and the ORR in all subgroups were consistent with the overall population. These results suggest that dose individualization of DARA SC on the basis of body weight is not necessary.

Table 3. Treatment-emergent adverse events.

| TEAE, n (%)   | DARA SC 1,800 mg (n=25) |
|--------------|-------------------------|
| All grades   | Grade 3 or 4            |
| >10%         | >1 patient              |
| Hematologic  |                         |
| Lymphopenia  | 8 (32.0)                | 5 (20.0) |
| Thrombocytopenia | 6 (24.0)                | 2 (8.0)  |
| Anemia       | 4 (16.0)                | 1 (4.0)  |
| Leukopenia   | 3 (12.0)                | 1 (4.0)  |
| Neutropenia  | 2 (8.0)                 | 2 (8.0)  |
| Non-hematologic |                     |
| Arthralgia   | 7 (28.0)                | 0        |
| Back pain    | 7 (28.0)                | 0        |
| Diarrhea     | 6 (24.0)                | 1 (4.0)  |
| Nasopharyngitis | 6 (24.0)                | 0        |
| Hypertension | 5 (20.0)                | 2 (8.0)  |
| Fatigue      | 5 (20.0)                | 1 (4.0)  |
| Asthenia     | 5 (20.0)                | 1 (4.0)  |
| Insomnia     | 5 (20.0)                | 1 (4.0)  |
| Nausea       | 5 (20.0)                | 0        |
| Headache     | 5 (20.0)                | 0        |
| Upper RTI    | 5 (20.0)                | 0        |
| Pyrexia      | 5 (20.0)                | 0        |
| Cough        | 5 (20.0)                | 0        |
| Vomiting     | 4 (16.0)                | 0        |
| Constipation | 4 (16.0)                | 0        |
| Musculoskeletal pain | 4 (16.0) | 0        |
| Oropharyngeal pain | 4 (16.0) | 0        |
| Bone pain    | 3 (12.0)                | 1 (4.0)  |
| Chills       | 3 (12.0)                | 0        |
| Peripheral edema | 3 (12.0) | 0        |
| Musculoskeletal chest pain | 3 (12.0) | 0        |
| Musculoskeletal discomfort | 3 (12.0) | 0        |
| Dyspnea      | 3 (12.0)                | 0        |

TEAE: treatment-emergent adverse event; DARA: daratumumab; SC: subcutaneous; RTI: respiratory tract infection.
There was a low incidence of anti-daratumumab antibodies with DARA SC, indicating a low risk of daratumumab immunogenicity following SC administration. Few patients (16%) were positive for treatment-emergent or treatment-induced anti-rHuPH20 antibodies; this rate is consistent with the immunogenicity rates reported for other rHuPH20-containing treatments (SC rituximab [9%], trastuzumab [20%], and immune globulin infusion HYQVIA [18%]).

The safety profile of DARA SC was consistent with the known profile of IV daratumumab; however, the frequency of IRR was lower with the SC administration than with the IV administration. The IRR rate with DARA SC was 16%, while IRR rates for IV administration of daratumumab range from 45% to 56% in monotherapy and combination regimens for RRMM. The majority of IRR occurred on day 1 of cycle 1. Only two patients experienced grade 3 IRR, and no cases of grade 4 IRR were reported. There were no discontinuations due to IRR or other TEAE. DARA SC injections in the periumbilical area were well tolerated; few injection-site TEAE were observed, and all objectively measured cases of erythema and induration were fully reversible and resolved within 1 h after the end of the injection.

Durable clinical responses were observed with DARA SC during this study, with a median duration of response of 15.7 months. Over time, the ORR improved, increasing from 44% to 52% after a median follow-up of 14.2 months, respectively, and responses deepened, with one patient achieving a complete response with longer follow-up. Despite the sample size of 25 patients, the median progression-free survival was 12.0 months among all-treated patients and 11.7 months among patients refractory to both PI and IMiD. An ORR of 52% is noteworthy in this population, with patients having received a median of three (range, 2-9) prior lines of therapy and 56% of patients being refractory to both PI and IMiD and 76% of patients being refractory to their last line of therapy. Clinical response rates achieved with DARA SC 1,800 mg were comparable to those achieved with daratumumab 16 mg/kg IV. In a pooled analysis of 148 patients with RRMM who received daratumumab 16 mg/kg IV in the monotherapy studies GEN501 and SIRIUS, the ORR was 31%, with 14% of patients achieving a very good partial response or better and 5% achieving a complete response or better. After a median follow-up of 20.7 months, the median progression-free survival was 4.0 months. The pooled patient population received a median of five (range, 2-14) prior lines of therapy, 87% were considered double refractory to a PI and an IMiD, and 91% were considered refractory to the last line of therapy.

In part 1 of PAVO, DARA-MD was administered by means of an infusion pump over a period of approximately 20 to 30 min. Compared with DARA-MD, the DARA SC formulation contains a higher concentration of daratumumab in a smaller injection volume (15 mL), thus enabling drug delivery through a single SC injection with a handheld syringe and needle by manual push into the abdominal wall over 3 to 5 min. As the median durations of the first, second, and subsequent daratumumab IV infusions in clinical studies were 7.0, 4.3, and 3.4 hours, respectively, DARA SC substantially shortens the duration of administration, thereby reducing the treatment
burden for patients and healthcare providers.

Findings from PAVO on the safety, PK, and efficacy profile of DARA SC informed four ongoing phase III studies of DARA SC 1,800 mg. In the randomized, multicenter, open-label, non-inferiority study, COLUMBA, DARA SC demonstrated non-inferiority to DARA 16 mg/kg IV in terms of ORR and maximum C_{trough} on day 1 of cycle 3, with a similar safety profile and a significantly reduced IRR rate, in patients with RRMM. Patient-reported outcome data from COLUMBA indicated that patients receiving DARA SC were more satisfied with their cancer therapy and had more positive perceptions of their treatment than patients receiving IV daratumumab. The efficacy and safety of DARA SC are also being investigated in combination with standard-of-care regimens in the phase II PLEIADES study, and results from this study demonstrate the feasibility of administering DARA SC in combination with standard-of-care regimens containing SC bortezomib. In PLEIADES, DARA SC in combination with SC bortezomib plus lenalidomide/dexamethasone and with SC bortezomib plus melphalan/prednisone in patients with newly diagnosed MM demonstrated comparable clinical activity and safety to the corresponding IV daratumumab regimens, with lower rates of IRR and shorter durations of administration. Although the dose of DARA SC on day 1 of cycle 1 should not be given at home, at-home administration of subsequent doses of DARA SC by a healthcare provider is a possibility for future consideration; however, additional safety follow-up is needed, particularly to further confirm that the risk of severe IRR with administration beyond the first day of cycle 1 is very low or absent.

Taken together, these findings show that DARA SC is well tolerated, with a low rate of IRR and a shortened administration time. No new safety concerns were identified, and the overall adverse event profile with SC administration was comparable to that reported with IV administration of daratumumab at the approved dose level (16 mg/kg). DARA SC achieved maximum C_{trough} values that were similar to or greater than the maximum C_{trough} observed for the approved 16 mg/kg IV dose following the same dosing schedule. DARA SC demonstrated robust clinical efficacy, producing deep and durable responses with a rapid onset. Collectively, these data indicate that, compared to the current IV formulation, DARA SC reduces administration time as well as IRR rates without compromising safety or efficacy. Based on these results, ongoing studies are actively investigating DARA SC in MM and other disease states.

Disclosures
JS-M has acted as a consultant for Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, Novartis, Takeda, Sanofi, and Roche. SZU has acted as a consultant for AbbVie, GlaxoSmithKline, Celgene, Amgen/Onyx, Takeda/Millennium, Sanofi, Seattle Genetics, Skyline, Merck, and Janssen; has received research funding from Celgene, Amgen/Onyx, Takeda/Millennium, Sanofi, Seattle Genetics, Skyline, Merck, Janssen, Array BioPharma, and Pharmacyclics; has served on speakers’ bureaus for Celgene, Amgen, Janssen, Sanofi, and Takeda; and has received travel expenses from Janssen, Celgene, Amgen, and Takeda. M-VM has received honoraria from and has acted as a consultant for Celgene, Janssen, Takeda, and Amgen. NWGvdD has received research support from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, and Bristol Myers Squibb and has served on advisory boards for Janssen Pharmaceuticals, Amgen, Celgene, Bristol Myers Squibb, Novartis, Bayer, Takeda, and Servier. JK has acted as a consultant or served in an advisory role for Janssen, Takeda, Celgene, Bristol Myers Squibb, Karyopharm Therapeutics, TG Therapeutics, Sanofi, Amgen, and Tecnofarma; has received research funding (institutional) from Merck, Celgene, Janssen, Sutro Biopharma, Fortis Therapeutics, Amgen, AbbVie/Genentech, and Bristol Myers Squibb; and has received travel and accommodation expenses from Janssen, Celgene, Bristol Myers Squibb, Sanofi, Amgen, and Takeda. PM has acted as a consultant for and received honoraria from Celgene, Takeda, and Janssen. AO has acted as a consultant for and received honoraria from Amgen, Takeda, and Janssen and has served on speakers’ bureaus for Amgen, Celgene, and Janssen. TP has received research support from Janssen Pharmaceuticals and served on advisory boards for Janssen Pharmaceuticals, Celgene, Takeda, and Belvoir. LB has acted as a consultant for and received honoraria from Takeda, Celgene, Janssen, and Amgen and has received travel expenses from Janssen, Celgene, and Amgen. KL, PH, TM, PLC, and AF are employees of Janssen. PH, TM, PLC, ML, and AF hold stock in Johnson & Johnson. AC has acted as a consultant for Amgen, Array BioPharma, Celgene, Janssen, Millennium, Takeda, and Novartis and has received research funding from Amgen, Array BioPharma, Celgene, Janssen, Millennium, Takeda, Novartis, and Pharmacyclics. HN has no conflicts of interest to report.

Contributions
All authors developed the manuscript, provided final submission approval, and confirmed that the protocol was followed and that the data were accurate and complete.

Acknowledgments
This study was sponsored by Janssen Research & Development, LLC. The authors would like to thank the patients who participated in this study and their families, as well as the study co-investigators, research nurses, and coordinators at each of the clinical sites. Medical writing and editorial support were provided by Kristin Runkle, PhD, of MedErgy, and were funded by Janssen Global Services, LLC.

Funding
The study was registered at ClinicalTrials.gov (NCT02519452) and was sponsored by Janssen Research & Development, LLC. Medical writing and editorial support were funded by Janssen Global Services, LLC. The data-sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

References
1. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematologic tumors. J Immunol. 2011;186(5):1840-1848.
2. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate antigen of CD38 antibodies MOR03087, SAR650964 and AB79. Blood. 2014;124(21):3474.
3. Overdijk MB, Verheogen S, Rogols M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs.
Overdijk MB, Jansen JH, Nederrand M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc receptor-mediated cross-linking. Blood 2016;127(5):807-813.

Krejci J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD56+ immune-regulatory cells, promotes T-cell expansion, and skewss T-cell repertoire in multiple myeloma. Blood 2016;128(3):384-394.

Chiu C, Casneuf T, Axel A, et al. Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLUX). Presented at: the 58th American Society of Hematology (ASH) Annual Meeting & Exposition; December 3-6, 2016; San Diego, CA. Abstract 4531.

Adams HC III, Stevenaert F, Krejci J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytotherapy. 2019;21(5):279-289.

DARZALEX® (daratumumab) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc; 2019.

European Medicines Agency. Summary of opinion (post authorisation). DARZALEX (daratumumab) https://www.ema.europa.eu/en/documents/smpc/chmp-post-authorisation-summary-positivedarzalex-ii-11_en.pdf. Published July 2018. Accessed August 2019.

Jakubowiak A, Chari A, Lonial S, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (D-Kd) in lenalidomide-refractory patients with relapsed multiple myeloma (MMY1001): an open-label, phase Ib study. Presented at: the Annual Meeting of the American Society of Clinical Oncology (ASCO); June 2-6, 2017; Chicago, IL. Abstract 8002.

Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide-refractory patients with relapsed multiple myeloma: subgroup analysis of MMY1001. Presented at: the Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1-5, 2018; Chicago, IL. Abstract 8002.

Scheid C, Munder M, Salwender H, Engelhardt M. Infusion of daratumumab in combination therapies - practical information for the outpatient area. Desch Med Wochenschr. 2018;143(16):1201-1206.

Barr H, Dempsey J, Waller A, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2016;30(2):2495-2508.

Halozyme Therapeutics. Mechanism of action for Hylenex recombinant (hyaluronidase human injection); www.hylenex.com/mechanism-of-action. Accessed August 2019.

Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): FAVO, an open-label, multicenter, dose escalation phase 1b study. Presented at: the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9-12, 2017; Atlanta, GA. Abstract 838.

US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.03. 2009. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_Sw.pdf. Accessed August 2019.

Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.

Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Working Group. Consensus Panel 1. Blood. 2011;117(11):4691-4695.

Yu XS, Yan X, Puchalaki T, et al. Clinical implications for complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma. Clin Pharmacol Ther. 2017;101(6):721-724.

Temers PA, Lee KM, Lokhov H, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56(9):915-924.

Wang DD, Zhang S, Zhao H, Men Y, Farivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49(9):1012-1024.

Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51(2):119-135.

Mateos MV, Usmani SZ, Grosicki S, et al. Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COULMBA. Presented at: the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2019; Chicago, IL. Abstract 8005.

Sonneveld P, Terpos E, Dimopoulos M, et al. Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): a multicenter, randomized, phase 3 study (AFOLLO). Presented at: the Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1-5, 2018; Chicago, IL. Abstract TS0009.

Rajkumar SV, Voorhees PA, Goldschmidt H, et al. Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): AQUILNA. J Clin Oncol. 2018;36(15 Suppl):TPS8062.

Comenzo RL, Kastritis E, Mauer M, et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed amyloid light chain (AL) amyloidosis: updated results from a randomized, double-blind, phase 3 study (AANDROMEDA). Presented at: the 24th European Hematology Association (EHA) Annual Congress; June 13-16, 2019; Amsterdam, The Netherlands. Abstract 8575.

Usmaei SZ, Mateos MV, Hungria V, et al. Greater treatment satisfaction in patients receiving subcutaneous versus intravenous daratumumab for relapsed or refractory multiple myeloma: a randomized trial. Blood 2019;134(8):668-677.

Lokhorst HM, Pesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(15):1207-1219.

Chari A, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016;128(14):1821-1828.

Chari A, Mark TM, Krishnan A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Presented at: the 58th American Society of Hematology (ASH) Annual Meeting & Exposition; December 3-6, 2016; San Diego, CA. Abstract 2142.

Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(7):974-981.

Lonial S, Weiss BM, Usmani S, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.

Mateos MV, Nahi H, Legiec W, et al. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COULMBA. Presented at: the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2019; Chicago, IL. Abstract 8005.

Usmani SZ, Akchurin H, McCarthy P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 2016;128(14):1821-1828.

Chari A, Mark TM, Krishnan A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Presented at: the 58th American Society of Hematology (ASH) Annual Meeting & Exposition; December 3-6, 2016; San Diego, CA. Abstract 2142.